Low frequency ultrasound combined with baicalein can reduced the invasive capacity of breast cancer cells by down regulating the expression of MMP-2, MMP-9, and u-PA

Qian Xi¹, Hang Qi¹, Yuan Li², Yan Xi³, Lei Zhang¹

¹Department of Radiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China; ²Department of Ultrasound, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China; ³Department of Ultrasound, Shanghai Quyang Hospital, Shanghai 200092, China

Contributions: (I) Conception and design: L Zhang; (II) Administrative support: L Zhang; (III) Provision of study materials or patients: Q Xi, H Qi; (IV) Collection and assembly of data: Y Li, Y Xi; (V) Data analysis and interpretation: Y Li, Y Xi; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Lei Zhang, MD. Department of Radiology, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China. Email: lei_zhang999@163.com.

Background: Over the past three decades, a large number of patients have died owing to breast cancer metastasis and recurrence. Therefore, there is an urgent need to develop effective and comprehensive strategies for the treatment of breast cancer. Earlier studies have demonstrated that low frequency ultrasound and baicalein can arrest the invasive activity of breast cancer cells and inhibit the migration and metastasis of breast cancer. However, the exact mechanism of action of this combination remains elusive. Furthermore, the inhibitory effect of the combination treatment with low frequency ultrasound and baicalein on breast cancer has not been reported.

Methods: In this study, human breast cancer cell line MDA-MB-231 was cultured and subjected to one of the following four treatment: low frequency ultrasound, baicalein, combination of the two, or no treatment. Cells in the low frequency group were irradiated with ultrasound for 5 min at a frequency of 840 kHz, 0.75 W/cm². Cells in the baicalein group were treated with baicalein for 24 h at a concentration of 150 μmol/L. In the combination group, cells were treated with both low frequency ultrasound and baicalein. Cells receiving no treatment were designated as the control group. Invasive capacity of cells in the four groups was examined by transwell assay. Matrix metalloproteinase 2 (MMP-2), MMP-9, and urokinase type plasminogen activator (u-PA) mRNA and protein levels were examined using Real-time PCR and Western blotting, respectively.

Results: The invasive capacity of cells in the low frequency group, baicalein group and the combination group was significantly reduced by 21.6%±1.68%, 31.9%±2.19% and 51.6%±2.01%, respectively. The expression levels of both mRNA and protein of MMP-2, MMP-9, and u-PA were significantly decreased in all three treatment groups, compared to that in the control group. The decline in the expression of MMP-2, MMP-9 and u-PA was highest in the combination group at both mRNA and protein levels.

Conclusions: Low frequency ultrasound combined with baicalein can effectively reduce the invasive capacity of breast cancer, probably by downregulating the expression of MMP-2, MMP-9, and u-PA.

Keywords: Low frequency ultrasound; baicalein; invasion; breast cancer
Breast cancer is the most common carcinoma and is considered as a major cause of cancer related death of women worldwide (1-3). Multiple factors that include a switch to western diet and increased stress (4) are believed to be associated with the initiation and progression of breast cancer (5,6). In China, the breast cancer incidence is relatively lower than that in the western countries, such as the United States (7). However, predictive models strongly suggest that breast cancer will soon reach epidemic proportions (8). Over the past three decades, many patients have died owing to breast cancer metastasis and recurrence. Therefore, there is an urgent need to develop effective and comprehensive strategies for the treatment of breast cancer.

Earlier studies have demonstrated that radiation with low frequency ultrasound can reduce DNA and protein synthesis, and reduce the invasive capacity of several types of cancer cells, including breast cancer cells (9). It has also been reported that baicalein, the active component of Chinese herbal medicine (skullcaps) can inhibit the migration and metastasis of breast cancer by arresting cell proliferation and promoting cell apoptosis (10). However, the exact mechanism underlying these effects has not been well understood. Furthermore, the effect of combined treatment with low frequency ultrasound and baicalein on the invasive capacity of breast cancer cells has not been reported.

In the current study, we examined the inhibitory effect of the combination of low frequency ultrasound and baicalein on the invasive activity of breast cancer cell line MDA-MB-231 and explored the potential underlying mechanism. The findings in this report will greatly aid the identification of potential targets for the development of novel and effective strategies for breast cancer treatment and prevent the metastasis and recurrence of breast cancer.

**Methods**

**Cell line**

The human breast cancer cell line MDA-MB-231 (ER−, PR−, HER2−) used in this study was purchased from ATCC. MDA-MB-231 cells are highly invasive and belong to the basal-B subtype. MDA-MB-231 cells were cultured in RPMI 1640 medium (Gibico, USA), supplemented with 10% FBS (Gibico, USA) and 1% penicillin/streptomycin (Gibico, USA) in a humidified incubator at 37 °C in 5% CO₂, and harvested with 0.25% trypsin–0.02% EDTA (Sigma, USA).

The cells were divided into four groups: low frequency ultrasound group, baicalein group, combination group and control group. Cells in the low frequency ultrasound group were irradiated with ultrasound using 838A ultrasonic therapy (SXUltrasonic biotech. CN). The probe was fixed on the bracket with the top side as the irradiation surface. Cells were placed in a centrifuge tube, and irradiated for 5 min at room temperature at a frequency of 840 kHz, 0.75 W/cm². Cells in the baicalein group were treated with baicalein at a final concentration of 150 μmol/L for 24 h. Cells in the combination group were first irradiated for 5 min at room temperature at a frequency of 840 kHz and an intensity of 0.75 W/cm², followed by baicalein treatment at a final concentration of 150 μmol/L for 24 h. Cells in the control group received no treatment.

**Transwell migration assay**

Cells (1×10⁵/well) in serum free RPM1640 were plated into the top chamber coated with 150 μg of Matrigel (BD Biosciences, USA). The bottom chamber contained 500 μL medium supplemented with 10% FBS. After incubation at 37 °C in 5% CO₂ for 24 h, the inserts were washed with water and the cells remaining on the upper surface of the membrane were removed with a cotton swab. The cells that migrated through the 8-mm sized pores and adhered to the lower surface of the membrane were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet and photographed. Five fields were counted under a microscope (Olympus, JPN). All assays were independently repeated thrice. The efficacy of the inhibition of invasion was calculated using the following formula:

Inhibitory efficacy (%)=(1 − invasive cell counts in observation group/invasive cell counts in control group) × 100%.

**Total RNA extraction**

Total RNA from cultured cells was extracted with Trizol (Applied Science, Germany) according to the manufacturer’s instructions. Briefly, cells were homogenized in 1 mL Trizol, transferred to a 1.5-mL RNase free tube, and incubated at RT for 5–10 min at which time, 0.2 mL Chloroform (Sigma, USA) was added to the tube and vortexed for 15 s. The mixture was allowed to sit at RT for 2–3 min before centrifuging at 12,000 g for 10 min at 4 °C. The aqueous layer (400 μL) was transferred to a new RNase free tube, mixed with 0.4 mL isopropyl alcohol, allowed
to stand at room temperature for 10 min to precipitate the RNA, and then centrifuged at 12,000 g for 5 min at 4 °C. The RNA pellet was washed with 75% EtOH. Finally, the pellet was air dried and re-suspended in DEPC H$_2$O. RNA purity and concentration were assayed using NanoDrop ND-1000 (NanoDrop Technologies, USA).

**Real-time PCR**

cDNA was synthesized using 2 μg of RNA and PrimeScript RT Reagent Kit (Takara, JPN) following the manufacturer’s instructions. Real-time PCR assay was performed in a ABI 7500 thermal cycler (ABI, USA) using SYBR Premix Ex Taq (Takara, JPN). The final real-time PCR mixture of 20 μL in a capillary tube comprised 2 μL cDNA, 10 μL SYBR Green Master Mix, 0.5 μL each of forward and reverse primers (10 pmol), and 7 μL of nuclease-free water. Melting curves were analyzed to confirm the synthesis of a single PCR product of each primer. GAPDH was amplified as an endogenous control and the fold change in expression of each target mRNA relative to that of GAPDH was calculated based on $2^{-\Delta\Delta CT}$ relative expression formula: $2^{-\Delta\Delta CT} = 2^{\Delta\Delta CT_{target
gene} - \Delta\Delta CT_{endogenous
gene}}$. The primer sequences of forward and reverse primers are shown in Table 1.

**Protein extraction**

Cells were homogenized in 400 μL RIPA for extracting total protein. The homogenate was subjected to sonication on ice for about 5 min, allowed to stand on ice for 30 min and then centrifuged for 10 min at 4 °C. The process was repeated one more time and protein concentration was determined by BCA. The extract containing 5 μg/μL protein was stored at −80 °C till further use.

**Western-blot**

Twenty-five micrograms of extracted proteins from each group were subjected to 10% denaturing SDS-PAGE and blotted onto PVDF membrane (400 mA, 90 min). The membranes were blocked with 1% BSA in TBST buffer for 30 min at 30 °C. Specific antibodies for matrix metalloproteinase 2 (MMP-2) (Santa Cruz, USA), MMP-9 (Abcam, USA), urokinase type plasminogen activator (u-PA) (Santa Cruz, USA) and GAPDH (Abcam, USA) were used as the primary antibodies at 1:2,000 dilution and incubated at 4 °C overnight. After washing thrice with TBST buffer (10 min/wash), the membranes were reacted with HRP-conjugated IgG as secondary antibody (Santa, USA) at 1:5,000 dilution and incubated at 37 °C for 1 h. After the final wash, the membranes were developed using Western Lightning ECL. Gray values of the bands were measured with Image J (NIH, USA) to obtain semi quantitative protein expressional levels.

**Statistical analysis**

Statistical analysis was conducted using SPSS 19.0 statistical package. All data were presented as mean ± SD. One-way ANOVA with Tukey HSD post hoc t-tests were used to analyze the differences in gene expressions between different groups. A P value of less than 0.05 was considered significant.

**Results**

**Reduced invasive activity of MDA-MB-231 cells**

In our study, the invasive activity of MDA-MB-231 cells was reduced significantly after different treatments (Figure 1). Specifically, the invasive activity was reduced by 21.6%±1.68% after low frequency ultrasound radiation, 31.9%±2.19% after baicalein treatment, and 51.6%±2.01% after combined treatment with low frequency ultrasound and baicalein. As can be seen from these results, the reduction in the invasive activity in the combination group was highest when compared with that in either ultrasound group or baicalein group (P<0.01) (Figure 2).
Reduced expression of MMP-2, MMP-9, and u-PA mRNA

RT-PCR was conducted to examine and analyze the changes in the expression of MMP-2, MMP-9, and u-PA at transcriptional level before and after treatment. As shown in Figure 3, the mRNA levels of MMP-2, MMP-9, and u-PA were significantly reduced after different treatments compared to that in the control group (all $P<0.01$). The mRNA levels of MMP-2, MMP-9, and u-PA were significantly lower in the combination group compared to those in the ultrasound group and the baicalein group. All the differences were all statistically significant ($P<0.01$).

Reduced expression of MMP-2, MMP-9, and u-PA proteins

To further elucidate the mechanism underlying the effect of different treatments on the invasive activity of MDA-MB-231 cells, expression of MMP-2, MMP-9, and u-PA at protein level, before and after the treatments, was analyzed by western blotting. The results showed that

Figure 1 The invasive capacity of MDA-MB-231 breast cancer cells was reduced after different treatments. Transwell migration assay was conducted to evaluate the invasive capacity of MDA-MB-231 breast cancer cells in the different experimental groups (crystal violet staining, 200x). (A) Control group; (B) low-frequency ultrasound group; (C) baicalein group; (D) combination group.

Figure 2 Inhibitory efficacy of the different treatments. The inhibitory efficacy was calculated after the different treatments. The results showed that the invasive activity was reduced by 21.6$\pm$1.68$\%$ after low frequency ultrasound radiation, 31.9$\pm$2.19$\%$ after baicalein treatment, and 51.6$\pm$2.01$\%$ after combined treatment with low frequency ultrasound and baicalein. As evidenced by these results, the reduction in the invasive activity was highest in the combination group compared to that in either ultrasound group or baicalein group. *, $P<0.01$, compared with either ultrasound group or baicalein group.
the protein levels of MMP-2, MMP-9 and u-PA were significantly reduced after different treatments compared to those in the control group (P<0.05). The protein levels of MMP-2, MMP-9, and u-PA were significantly lower in the combination group compared to those in the ultrasound group and the baicalein group. All the differences were all statistically significant (P<0.05) (Figure 4, Table 2).

Discussion

Tumor metastasis is defined as the process of primary tumors invading and metastasizing to the surrounding or distal tissues and organs. It was reported that tumor cells can pass through the extracellular matrix via epithelial mesenchymal cell transformation (EMT) (11). In addition, tumor cells can secrete soluble proteolytic enzymes such as MMPs and u-PA to degrade the extracellular matrix, leading to the destruction of the basement membrane and metastasis to distant tissues and organs (12).

Baicalein is one of the important components in a Chinese herbal medicine, skullcaps. It has multiple pharmacological effects, including immune function regulation, anti-inflammation, and helps in reducing blood lipids (13). Recent reports in the literature showed that baicalein can inhibit cell proliferation, invasion and metastasis, and regulate signal transduction in several solid tumors, including breast cancer (14). Previous studies have demonstrated that tumor cells may be more susceptible to ultrasound radiation, when compared to normal cells, and that ultrasound can kill tumor cells by cavitation effect (15,16). Low frequency ultrasound presents several advantages, including fewer adverse biological effects and reduced drug resistance (17). In our study, we demonstrated, by using transwell migration assay, that baicalein and low frequency ultrasound treatment can reduce the invasive
capacity of MDA-MB-231 breast cancer cells, which was consistent with previous studies (15-17). Furthermore, our study found that the combined use of the two treatments had stronger inhibitory effect on the invasive capacity of breast cancer cells compared to either one of the treatments individually, indicating the synergistic effect of the two treatments. To our knowledge, this is the first study to report the combined use of low frequency ultrasound and baicalein in the treatment of breast cancer, and revealed the synergistic effect of the two treatments.

In order to further explore the potential molecular underlying mechanism, the expression levels of tumor invasion associated molecules, such as MMPs and u-PA, were examined at both the transcriptional and translational levels. MMPs are widely expressed in tumor cells, and participate in a variety of tumor-specific behaviors, including invasion and metastasis (12). MMPs can degrade collagen fibers, thereby enabling the tumor cells to migrate into the surrounding environment. Accumulating evidence indicates that MMPs, specifically MMP-2 and MMP-9, are associated with the invasion and metastasis in breast cancer (18). u-PA is a type of protease, that can degrade the basement membrane components around the tumor tissue by proteolytic hydrolysis. It was demonstrated that downregulation of u-PA can inhibit the invasive capacity of BT-549 breast cancer cells (19). The results of this study showed that the expression levels of MMP-2, MMP-9, and u-PA were downregulated at both the protein and mRNA levels after treatment with either low frequency ultrasound or baicalein. We further examined the changes in the expression of these genes in the combination group, and the results showed that the reduction in the expression of MMP-2, MMP-9, and u-PA at both the transcriptional and translational levels was significantly higher in the combination group compared to that with either treatment alone. These results further confirmed the synergistic effect of the two treatments, and indicated that the combined use of low frequency ultrasound and baicalein may be the optimal strategy for breast cancer therapy.

This study has some limitations. Firstly, only a few of the tumor invasion associated molecules were examined in this study, since this was a preliminary study. Secondly, the effects of MMPs and u-PA on the invasion of breast cancer cells were not further validated by reinstating the expression of these molecules. Thirdly, it is necessary to further confirm these findings in vivo by using tumor bearing mice or other animal models. Further research is needed to explore the exact mechanism underlying the inhibitory effects of low frequency ultrasound and baicalein on breast cancer invasion and their synergistic effects in vitro and in vivo.

In summary, our study results indicated that the combined use of low frequency ultrasound and baicalein was a novel and optimized strategy for breast cancer therapy, which resulted in better inhibitory effect on the invasion of MDA-MB-231 breast cancer cells, probably by downregulating the expression of MMP-2, MMP-9, and u-PA. The findings of this study will be helpful in the identification of potential targets for targeted treatment of breast cancer, and further development of this novel therapeutic strategy.

Acknowledgements

Funding: This work was partially supported by the National Natural Science Foundation of China (Grant No. 81301200, 81201069).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Table 2 Gray values of MMP-2, MMP-9 and uPA

<table>
<thead>
<tr>
<th>Group</th>
<th>MMP-2/GAPDH</th>
<th>MMP-9/GAPDH</th>
<th>uPA/GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low frequency ultrasound</td>
<td>0.71±0.01*</td>
<td>0.76±0.01*</td>
<td>0.77±0.02*</td>
</tr>
<tr>
<td>Baicalein</td>
<td>0.71±0.02*</td>
<td>0.69±0.01*</td>
<td>0.68±0.02*</td>
</tr>
<tr>
<td>Combined</td>
<td>0.53±0.01*</td>
<td>0.51±0.02*</td>
<td>0.55±0.01*</td>
</tr>
<tr>
<td>Control</td>
<td>0.96±0.01</td>
<td>0.91±0.01</td>
<td>0.93±0.01</td>
</tr>
</tbody>
</table>

*P<0.05, when compared with the control group; P<0.05, when compared with either low frequency ultrasound group or baicalein group.
References